Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
AstraZeneca
Paul DiSilvestro; Susana Banerjee; Nicoletta Colombo; Giovanni Scambia; Byoung-Gie Kim; Ana Oaknin; Michael Friedlander; Alla Lisyanskaya; Anne Floquet; Alexandra Leary; Gabe S Sonke; Charlie Gourley; Amit Oza; Antonio González-Martín; Carol Aghajanian; William Bradley; Cara Mathews; Joyce Liu; John McNamara; Elizabeth S Lowe; Mei-Lin Ah-See; Kathleen N Moore; SOLO1 Investigators
Biostatistics, Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.